Total Payments
$2.4M
2024 Payments
$12,535
Companies
27
Transactions
345
Medicare Patients
41,340
Medicare Billing
$41.7M
Payment Breakdown by Category
Other$2.2M (91.1%)
Research$187,329 (7.9%)
Consulting$9,326 (0.4%)
Food & Beverage$8,134 (0.3%)
Travel$5,370 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Current or prospective ownership or investment interest | $1.6M | 15 | 66.9% |
| Acquisitions | $574,320 | 1 | 24.2% |
| Unspecified | $187,329 | 50 | 7.9% |
| Consulting Fee | $9,326 | 2 | 0.4% |
| Food and Beverage | $8,134 | 260 | 0.3% |
| Travel and Lodging | $5,370 | 14 | 0.2% |
| Entertainment | $167.55 | 3 | 0.0% |
Payments by Type
General
$2.2M
295 transactions
Research
$187,329
31 transactions
Ownership
$0
19 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| US Retina LLC | $2.2M | 45 | $0 (2024) |
| Allergan, Inc. | $131,095 | 69 | $0 (2021) |
| Genentech, Inc. | $55,528 | 13 | $0 (2023) |
| Amgen Inc. | $10,883 | 11 | $0 (2024) |
| Genentech USA, Inc. | $2,888 | 97 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $2,103 | 7 | $0 (2017) |
| F. Hoffmann-La Roche AG | $1,004 | 1 | $0 (2020) |
| ABBVIE INC. | $646.98 | 27 | $0 (2024) |
| Alcon Vision LLC | $509.67 | 6 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $460.90 | 22 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,535 | 56 | Amgen Inc. ($10,883) |
| 2023 | $55,398 | 47 | Genentech, Inc. ($54,161) |
| 2022 | $274,039 | 45 | US Retina LLC ($272,697) |
| 2021 | $858,155 | 28 | US Retina LLC ($857,550) |
| 2020 | $301,724 | 21 | US Retina LLC ($300,484) |
| 2019 | $364,768 | 48 | US Retina LLC ($363,765) |
| 2018 | $371,404 | 35 | US Retina LLC ($369,737) |
| 2017 | $133,190 | 65 | Allergan Inc. ($130,341) |
All Payment Transactions
345 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $29.95 | General |
| Category: EYE CARE | ||||||
| 12/07/2024 | US Oncology Corporate, Inc. | — | Food and Beverage | Cash or cash equivalent | $28.62 | General |
| 12/05/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $2.61 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/21/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $14.29 | General |
| Category: EYE CARE | ||||||
| 11/20/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $77.77 | General |
| Category: EYE CARE | ||||||
| 10/18/2024 | Genentech USA, Inc. | Susvimo (Drug), Vabysmo | Food and Beverage | In-kind items and services | $93.75 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/17/2024 | Alcon Vision LLC | Constellation (Device) | Food and Beverage | In-kind items and services | $135.53 | General |
| Category: Ophthalmology | ||||||
| 10/01/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $95.63 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/01/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $24.67 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/21/2024 | Alcon Vision LLC | Constellation (Device) | Food and Beverage | In-kind items and services | $94.53 | General |
| Category: Ophthalmology | ||||||
| 09/21/2024 | Alcon Vision LLC | Constellation (Device) | Food and Beverage | In-kind items and services | $40.45 | General |
| Category: Ophthalmology | ||||||
| 09/20/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $105.78 | General |
| Category: Ophthalmology | ||||||
| 08/28/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $94.77 | General |
| Category: Cardiovascular | ||||||
| 08/22/2024 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Food and Beverage | In-kind items and services | $19.37 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
| 08/20/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $13.63 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 08/15/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $18.26 | General |
| Category: EYE CARE | ||||||
| 08/07/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $18.39 | General |
| Category: Immunology and Ophthalmology | ||||||
| 07/24/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $23.38 | General |
| Category: Immunology and Ophthalmology | ||||||
| 07/09/2024 | Biogen, Inc. | BYOOVIZ (Biological) | Food and Beverage | In-kind items and services | $18.61 | General |
| Category: Ophthalmology | ||||||
| 06/26/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $20.31 | General |
| Category: Immunology and Ophthalmology | ||||||
| 06/25/2024 | Amgen Inc. | PAVBLU (Biological) | Consulting Fee | Cash or cash equivalent | $4,826.25 | General |
| Category: Inflammation | ||||||
| 06/25/2024 | Amgen Inc. | PAVBLU (Biological) | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| Category: Inflammation | ||||||
| 06/25/2024 | Amgen Inc. | PAVBLU (Biological) | Travel and Lodging | Cash or cash equivalent | $67.35 | General |
| Category: Inflammation | ||||||
| 06/20/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $16.17 | General |
| Category: EYE CARE | ||||||
| 06/14/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $21.44 | General |
| Category: Immunology and Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration | Allergan Inc. | $130,060 | 17 |
| Phase 2 of RO7171009 in GA | Genentech, Inc. | $54,161 | 6 |
| A PHASE 3, DOUBLE-MASKED, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTION IN PATIENTS WITH MODERATELY SEVERE TO SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY | Regeneron Pharmaceuticals, Inc. | $2,103 | 7 |
| Check A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION, A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION | F. Hoffmann-La Roche AG | $1,004 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 9,457 | 106,585 | $40.2M | $11.4M |
| 2022 | 26 | 10,900 | 54,305 | $35.5M | $10.5M |
| 2021 | 27 | 10,379 | 42,735 | $32.2M | $10.1M |
| 2020 | 24 | 10,604 | 41,025 | $29.7M | $9.7M |
Total Patients
41,340
Total Services
244,650
Medicare Billing
$41.7M
Procedure Codes
100
All Medicare Procedures & Services
100 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 524 | 6,708 | $12.4M | $4.6M | 36.9% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 169 | 60,900 | $5.7M | $1.8M | 30.8% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 297 | 8,824 | $8.8M | $1.6M | 18.0% |
| J3490 | Unclassified drugs | Office | 2023 | 216 | 553 | $3.0M | $974,493 | 32.3% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 236 | 7,005 | $2.6M | $839,741 | 32.8% |
| 67028 | Injection of drug into eye | Office | 2023 | 1,065 | 5,915 | $4.6M | $556,118 | 12.1% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 1,750 | 5,748 | $1.3M | $492,049 | 36.7% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2023 | 62 | 1,365 | $535,380 | $215,217 | 40.2% |
| 92134 | Imaging of retina | Office | 2023 | 2,079 | 5,976 | $534,732 | $177,821 | 33.3% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 590 | 759 | $121,820 | $44,085 | 36.2% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 35 | 38 | $115,343 | $33,259 | 28.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 185 | 185 | $59,814 | $21,327 | 35.7% |
| 92250 | Photography of the retina | Office | 2023 | 668 | 758 | $109,804 | $20,431 | 18.6% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 110 | 238 | $59,500 | $15,415 | 25.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 205 | 231 | $32,192 | $14,323 | 44.5% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2023 | 22 | 22 | $42,089 | $13,426 | 31.9% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 109 | 112 | $28,871 | $9,672 | 33.5% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 727 | 800 | $48,800 | $8,479 | 17.4% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 108 | 134 | $24,924 | $4,577 | 18.4% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 103 | 106 | $17,787 | $4,533 | 25.5% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Office | 2023 | 21 | 23 | $24,761 | $3,481 | 14.1% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 158 | 167 | $10,187 | $2,847 | 27.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 18 | 18 | $3,772 | $1,399 | 37.1% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 610 | 7,778 | $14.4M | $5.5M | 38.1% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 347 | 10,548 | $10.5M | $2.3M | 22.2% |
About Dr. Sunil Gupta, M.D
Dr. Sunil Gupta, M.D is a Ophthalmology healthcare provider based in Pensacola, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1063489383.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sunil Gupta, M.D has received a total of $2.4M in payments from pharmaceutical and medical device companies, with $12,535 received in 2024. These payments were reported across 345 transactions from 27 companies. The most common payment nature is "Current or prospective ownership or investment interest" ($1.6M).
As a Medicare-enrolled provider, Gupta has provided services to 41,340 Medicare beneficiaries, totaling 244,650 services with total Medicare billing of $41.7M. Data is available for 4 years (2020–2023), covering 100 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Ophthalmology, Retina Specialist
- Location Pensacola, FL
- Active Since 03/06/2006
- Last Updated 02/21/2018
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1063489383
Products in Payments
- PAVBLU (Biological) $10,883
- EYLEA AFLIBERCEPT INJECTION (Biological) $2,208
- Non-Covered Product (Drug) $2,153
- OZURDEX (Drug) $1,596
- Lucentis (Biological) $1,388
- Vabysmo (Drug) $941.32
- Constellation (Device) $488.55
- YUTIQ (Drug) $376.55
- VABYSMO (Drug) $285.11
- Syfovre (Drug) $283.14
- EYLEA (Biological) $248.21
- NGENUITY (Device) $202.53
- California (Device) $167.55
- Susvimo (Drug) $166.72
- EYLEA HD (Biological) $108.41
- CAMZYOS (Drug) $94.77
- NORTHERA (Drug) $89.48
- BEOVU (Drug) $85.23
- BYOOVIZ (Biological) $69.41
- XIPERE (Drug) $57.43
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Pensacola
John Myers, M.d, M.D
Ophthalmology — Payments: $177,173
Ophthalmology $177,173
Dr. Jennifer Murray, Md, MD
Ophthalmology — Payments: $12,772
Ophthalmology $12,772
Dr. Timothy Mclaughlin, Md, MD
Ophthalmology — Payments: $9,271
Ophthalmology $9,271
Dr. Richard Livernois, M.d, M.D
Ophthalmology — Payments: $6,727
Ophthalmology $6,727
Dr. Jerry Suelflow, Md, MD
Ophthalmology — Payments: $5,714
Ophthalmology $5,714
Dr. William Aldred, Md, MD
Ophthalmology — Payments: $5,052
Ophthalmology $5,052